Oncobiologics (NASDAQ:OTLK) Trading Up 4.5% - Still a Buy?

Shares of Oncobiologics, Inc. (NASDAQ:OTLK - Get Free Report) shot up 4.5% during mid-day trading on Monday . The company traded as high as $2.00 and last traded at $1.86. 1,434,782 shares traded hands during trading, an increase of 72% from the average session volume of 833,658 shares. The stock had previously closed at $1.78.

Analyst Ratings Changes

A number of brokerages have issued reports on OTLK. Guggenheim reiterated a "buy" rating on shares of Oncobiologics in a research report on Tuesday, May 20th. Ascendiant Capital Markets cut their price objective on Oncobiologics from $24.00 to $21.00 and set a "buy" rating for the company in a report on Friday, June 6th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $9.60.

Oncobiologics Stock Performance

The stock has a 50 day moving average of $1.70 and a two-hundred day moving average of $1.68. The stock has a market cap of $62.44 million, a PE ratio of -2.04 and a beta of 0.25.

Oncobiologics (NASDAQ:OTLK - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.15. Analysts expect that Oncobiologics, Inc. will post -2.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OTLK. Rhumbline Advisers raised its position in Oncobiologics by 1,329.6% during the fourth quarter. Rhumbline Advisers now owns 188,050 shares of the company's stock valued at $355,000 after buying an additional 174,896 shares during the period. Bank of New York Mellon Corp increased its position in Oncobiologics by 44.8% in the 4th quarter. Bank of New York Mellon Corp now owns 29,764 shares of the company's stock worth $56,000 after purchasing an additional 9,211 shares during the last quarter. Commonwealth Equity Services LLC acquired a new position in Oncobiologics in the 4th quarter worth about $48,000. Russell Investments Group Ltd. increased its position in Oncobiologics by 34,936.7% in the 4th quarter. Russell Investments Group Ltd. now owns 17,168 shares of the company's stock worth $32,000 after purchasing an additional 17,119 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in Oncobiologics in the 4th quarter worth about $246,000. 11.20% of the stock is owned by institutional investors and hedge funds.

Oncobiologics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.